NEW YORK– Wedbush Securities, a global independent financial services firm, is pleased to announce the appointment of Yun Zhong, PhD, as Senior Vice President, Equity Research, specializing in biotechnology. Zhong initiates coverage on eight stocks focused on various biotech sectors, including Ascendis Pharma (ASND), BioMarin Pharmaceuticals (BMRN), Keros Therapeutics, Inc. (KROS), MoonLake Immunotherapeutics (MLTX), Passage Bio (PASG), Protagonist Therapeutics (PTGX), Rezolute, Inc. (RZLT) and Voyager Therapeutics (VYGR). This marks the first phase of a broader launch of coverage that will continue to expand the depth of names under Wedbush’s distinguished Healthcare Equity Research team.
Joining from Jefferies, Zhong brings a deep understanding of therapeutic mechanisms and emerging biotech trends with his expertise spanning orphan diseases, genetic medicine, hematology, neuromuscular diseases and metabolic disorders. Zhong’s journey began at Cowen and Company, followed by senior positions at SunTrust Robinson Humphrey, Janney Montgomery Scott, Berenberg Capital Markets and BTIG.
Zhong comments, “Joining Wedbush is a fantastic opportunity to be part of a firm with a strong reputation and a well-established presence in biotech. The collaborative and collegial atmosphere here is exceptional, and I am eager to contribute to the research being conducted by this talented team.”
Kevin Merritt, Director of Research, adds, “Yun’s technical expertise and deep understanding of the field will greatly enhance our Healthcare Research team. His insights will be invaluable as we continue to provide our clients with top-tier analysis and support in this dynamic sector.”
Zhong earned his PhD in neuroscience and molecular biology from Rockefeller University and holds both a Master of Science and a Bachelor of Science in biophysical engineering from Osaka University in Japan.
